EXIT071 (EXosomes Isolation Tool developed @Leiden) – an innovative startup developing pioneering technology for the analysis of novel biomarkers exosomes. All cells in our body make exosomes to send messages to other cells. Cells pack these tiny bubbles with their own molecular information and excrete them into all body fluids – blood, urine and even tears! Using exosomes make diagnostics very specific. This is why exosomes have a huge potential for non-invasive diagnostics and novel therapeutics. At EXIT071 we develop microfluidic technology that allows for the isolation and analysis of exosomes with high purity and in high-throughput automated format.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Langegracht 70, Leiden,south Holland 2312nv,netherlands
- Industry
- Research
- Website
- http://www.exit071.com
- Keywords
- Hybridize Therapeutics.
- HQ
- Leiden, South Holland
Exit071 Questions
Exit071's website is http://www.exit071.com
Exit071's LinkedIn profile is https://nl.linkedin.com/company/exit071
Exit071 has
6 employees.
View email and phone details for 6
employees at Exit071.
Exit071's industry is
Research
Exit071's top competitors are
Idris Oncology Bv,
Leiden Bio Science Park,
Medical Delta,
Imuno Therapeutics,
Biotech Booster,
Hybridize Therapeutics,
Rapidemic,
Necstgen,
Vitroscan,
Alesta Therapeutics.
Exit071's categories are Research
Exit071's founding year is 2021
